Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Academic and Community Cancer Research United: Clinical Trials & FDA Approval Profile

Academic and Community Cancer Research United (Global / Institutional) sponsors 25 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 10 active protocols (4 recruiting now), 2 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)32.0%
Median Closed Enrollment vs National (145 pts)17 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Academic and Community Cancer Research United
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)25
Active Pipeline (Recruiting Now)10 (4)
Completed vs Stopped Early2 / 8 (32.0%)
Median Closed Actual Enrollment17 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Academic and Community Cancer Research United
Hospital Research SiteLocationShared Protocols
Mayo Clinic RochesterRochester, MN17
Mayo Clinic ArizonaPhoenix, AZ11
Mayo Clinic FloridaJacksonville, FL8

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Academic and Community Cancer Research United
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05168163Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver CancerPhase IIRECRUITING
NCT04660760Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or GastroesophagPhase IIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Academic and Community Cancer Research United Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI